American College of Clinical Pharmacy
      Search      Cart
         

PSAP in JACCP - Part I: Interactive Case: Psoriasis and Part II: Interactive Case: Combination Therapies in BPH - 2022 June


Member Price:
$29.95
Nonmember Price:
$29.95

Faculty Information

PSAP in JACCP features are developed from activities presented as part of the Pharmacotherapy Self-Assessment Program (PSAP).

Part I: Interactive Case: Psoriasis

This feature was developed from an interactive case presented in PSAP 2021 Book 3 (Chronic Conditions and Public Health).

  • Interactive Case: Click here to access the interactive case.
Part II: Interactive Case: Combination Therapies in BPH

This feature was developed from an interactive case presented in PSAP 2021 Book 3 (Chronic Conditions and Public Health).

  • Interactive case: Click here to access the interactive case.

Author - Reviewer Information

Part I: Interactive Case: Psoriasis

Author: Timothy D. Gladwell, Pharm.D., BCPS, BCACP
Reviewed by: Rebecca M. Law, Pharm.D.; Ann Nadrash, Pharm.D., BCPS; and Kimberly N. Blanton, Pharm.D., BCPS

Part II: Interactive Case: Combination Therapies in BPH

Authors: Mary Barna Bridgeman, Pharm.D., FCCP, FNAP, BCPS, BCGP; and Luigi Brunetti, Pharm.D., MPH, BCPS, BCGP
Reviewed by: Kathy Eroschenko, Pharm.D.; Tara B. Vlasimsky, Pharm.D., BCPS, BCACP; and Daniel Majerczyk, Pharm.D., BCPS, BC-ADM, CACP

Target Audience and Learning Objectives

Part I: Interactive Case: Psoriasis

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic disease and need for public health–related services.

Learning Objectives

  1. Apply data from contemporary studies of epidemiology and pathophysiology to the assessment and treatment of patients with psoriasis.
  2. Evaluate the severity of a patient’s psoriasis in order to justify a general treatment approach.
  3. Develop an evidence-based treatment regimen to manage the clinical manifestations of a patient’s psoriasis.
  4. Develop a plan for screening and managing psoriasis-related comorbidities and adverse effects of therapy according to current guidelines.
  5. Design a treatment plan to manage special populations of patients with psoriasis.
Part II: Interactive Case: Combination Therapies in BPH

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic disease and need for public health–related services.

Learning Objectives

  1. Evaluate combination pharmacologic agents for the treatment of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), including adverse effects and monitoring.
  2. Design an appropriate treatment approach for a patient with BPH/LUTS, including the role of combination therapy.

Disclosure of Potential Conflicts of Interest

Part I: Interactive Case: Psoriasis

Rebecca Law: Royalties (McGraw-Hill, Springer Nature); Consultancies (Memorial University of Newfoundland); Honoraria (Memorial University of Newfoundland Faculty of Medicine
Kimberly N. Blanton; Timothy D. Gladwell; Ann Nadrash: Nothing to disclose

Part II: Interactive Case: Combination Therapies in BPH

Mary Barna Bridgeman: Grants (Merck and Co.); Honoraria (AstraZeneca)
Luigi Brunetti: Consultancies (Tabula Rasa Healthcare, Horizon Blue Cross Blue Shield of New Jersey); Grants (Merck and Co., CSL Behring, Innovative Research)
Kathy Eroschenko: Grants (Idaho Office of Drug Policy)
Tara B. Vlasimsky: Stock Ownership (Imidex)
Daniel Majerczyk: Nothing to disclose

Continuing Pharmacy Education and Recertification Instructions

Available CPE/Recertification credits: Anyone who purchases, successfully completes and passes the required posttests for this feature can earn up to 3.0 contact hours of CPE/Recertification credit.

Part I: Interactive Case: Psoriasis

Universal Activity Number: 0217-0000-22-072-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Combination Therapies in BPH

Universal Activity Number: 0217-0000-22-073-H04-P
1.5 CPE contact hours
Application-Based Activity

Release date: June 8, 2022
BCPS posttest submission deadline: 11:59 p.m. (Central) on December 8, 2022.
ACPE posttest submission deadline: 11:59 p.m. (Central) on June 8, 2025.

TO EARN CPE/RECERTIFICATION CREDIT FROM THIS FEATURE
Posttest access: Purchase the required posttests (see below); then go to www.accp.com and sign in with your e-mail address and password. PSAP in JACCP features are listed under My Products on your My Account page.
Technical support is available from 8 a.m. to 5 p.m. (Central) weekdays by e-mail at [email protected].

Release Date: June 08, 2022
BCPS Deadline: December 08, 2022
ACPE Deadline: June 08, 2025

Format: Online Test

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American College of Clinical Pharmacy is approved by BPS as a provider for the recertification of BCPS.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.


Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.